NasdaqCM - Nasdaq Real Time Price ? USD Revelation Biosciences, Inc. (REVB) Follow Compare 0.8499 -0.0031 (-0.36%) At close: 4:00 PM EDT 0.8599 +0.01 (+1.18%) After hours: 7:32 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 SAN DIEGO, September 24, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data fr Business Wire ? 23 days ago REVB -0.36% REVBW Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds SAN DIEGO, August 21, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock, issued by the Company on February 5, 2024 (the "Existing Warrants"), at the reduced ex Business Wire ? last month REVB -0.36% REVBW REVB: Bolsters Cash Amid Positive Trial Results By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) announced its 2Q2024 financial results which showed, on the heels of exciting testing announcements detailed below, good cash on hand that the company says is at least enough to finance operations through the end of the year. Clinical stage companies are often in a cash crunch, and we are Zacks Small Cap Research ? 2 months ago REVBW Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 SAN DIEGO, August 09, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Business Wire ? 2 months ago REVB -0.36% REVBW REVB Releases Positive Test Results—Potential Catalyst By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl Zacks Small Cap Research ? 3 months ago REVBW Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday? On Monday, Revelation Biosciences Inc (NASDAQ:REVB) announced safety and biomarker data for its Phase 1 study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified. Additionally, statistically significant dose-dependent upregulation of key biomarkers demonstrating the immunostimulatory preconditioning effect of Gemini was observed. The study enrolled 40 healthy individuals 1 Benzinga ? 3 months ago REVBW Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity SAN DIEGO, June 24, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified. Ad Business Wire ? 3 months ago REVB -0.36% REVBW Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini SAN DIEGO, June 13, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy ind Business Wire ? 4 months ago REVB -0.36% REVBW REVB: In Great Position For Testing By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl Zacks Small Cap Research ? 5 months ago REVBW Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 SAN DIEGO, May 10, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Business Wire ? 5 months ago REVB -0.36% REVBW REVB Begins Trials with Good Cash on Hand By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVBRESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl Zacks Small Cap Research ? 6 months ago REVBW Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 SAN DIEGO, March 22, 2024--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results. Business Wire ? 6 months ago REVB -0.36% REVBW Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) SAN DIEGO, March 13, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place Business Wire ? 7 months ago REVB -0.36% REVBW Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference SAN DIEGO, March 12, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California. Business Wire ? 7 months ago REVB -0.36% REVBW Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini SAN DIEGO, March 04, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation") a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has commenced a first in human Phase 1 clinical study (RVL-HV02) to evaluate escalating doses of intravenously administered Gemini. The study is being conducted in Australia and is enrolling healthy individuals 18 to 55 years of a Business Wire ? 7 months ago REVB -0.36% REVBW Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) SAN DIEGO, February 13, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, as part of a limited number of accepted abstract authors, the company was invited to give an oral presentation of new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) at The 29th International Conference on Advances in Critical Care Nephrology taking place in San Diego from March 12-15, 2024. Gemini is the C Business Wire ? 7 months ago REVB -0.36% REVBW Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering SAN DIEGO, February 05, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing on February 5, 2024 of its previously announced public offering of 128,470 shares of its common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its Business Wire ? 8 months ago REVB -0.36% REVBW Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering SAN DIEGO, February 01, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the pricing of a public offering of 1,365,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of $4.53 per share and associate Business Wire ? 8 months ago REVB -0.36% REVBW Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) SAN DIEGO, January 30, 2024--Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024). Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD?), a toll Business Wire ? 8 months ago REVB -0.36% REVBW REVB Continues March to Trials By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl Zacks Small Cap Research ? 8 months ago REVBW Performance Overview Trailing total returns as of 10/17/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return REVB S&P 500 YTD -94.35% +22.47% 1-Year -95.71% +33.56% 3-Year -99.99% +30.64%
